Suppression of hepatitis C virus replication during COVID‐19 infection

Jang, Tyng‐Yuan

doi:10.1002/kjm2.12498

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, individuals with underlying liver cirrhosis have an even higher relative risk [18]. It has been suggested that the replication of hepatitis C virus (HCV) may be inhibited during infection with SARS-CoV-2, but due to a lack of HCV RNA measurements, the complete viral load curve cannot be confirmed [19].…”

Section: Discussionmentioning

confidence: 99%

Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate

Hsu,

Yang,

Hou

et al. 2023

Life

View full text Add to dashboard Cite

This study retrospectively analyzed the medical records of 602 patients with first-time positive results for the HCV nucleic acid test between 1 May 2021 and 31 March 2023, exploring the association between DAA treatment and SARS-CoV-2 infection. The results showed that 9.8% of HCV patients were co-infected with SARS-CoV-2. Gender, age, vaccination status, and HCV genotype did not significantly affect SARS-CoV-2 infection. However, patients undergoing DAA treatment showed significantly lower rates of SARS-CoV-2 infection and mortality compared to those not undergoing DAA treatment. The analysis also compared patients undergoing different DAA treatments, with Epclusa and Maviret showing superior protection against SARS-CoV-2. Furthermore, this study explored the severity and mortality of SARS-CoV-2 infection in patients undergoing and having completed DAA treatment. It revealed that patients diagnosed with COVID-19 during DAA treatment experienced only mild symptoms, and none died, suggesting a potential protective effect of DAA treatment against severe outcomes of SARS-CoV-2 infection. The findings contribute to the understanding of the interplay between HCV, DAA treatment, and SARS-CoV-2 infection, highlighting the need for continued monitoring and healthcare measures for individuals with chronic conditions during the ongoing COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate

Hsu,

Yang,

Hou

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…Важно заметить, что, согласно данным литературы, используемый у пациентки препарат не обладает свой ством усиления репликации HCV. В дальнейшем у пациентки установили генотип вируса (1b) и начали соответствующее лечение [47].…”

Section: гиперферритинемия у пациентов с Covid-19 и хгсunclassified

Hyperferritinemia, chronic hepatitis C and COVID-19: what do they have in common?

2023

View full text Add to dashboard Cite

Ferritin is one of the key proteins, which has involved in the regulation of iron homeostasis in the body. Ferritin reduced values are often associated with changes in the total iron supply in the body. In addition, ferritin is involved in immune processes and can have both pro-inflammatory and anti-inflammatory effects. Ferritin changes in laboratory values is a rather nonspecific sign that occurs with immunoinflammatory and infectious diseases, as well as the development of iron overload. It can, among other things, accompany the course of new coronavirus infection (COVID-19) and chronic viral hepatitis C (CHC) in patients. Hyperferritinemia in these two diseases may be a marker of a more severe course and adverse patient outcome, making the study of ferritin levels an extremely important task for the practitioner. Therefore, the purpose of this review of the scientific literature was to investigate the possible relationship between Hyperferritinemia, COVID-19 and CHC. It has been reported that hyperferritinemia is quite often associated with a more severe form of both COVID-19 and CHC. Several studies have suggested that the risk of mortality may be increased if they are combined. In this regard, an important conclusion was made about measuring baseline ferritin levels with subsequent dynamic monitoring in this group of patients.

show abstract

Reactivación y coinfecciones virales en COVID-19: otro elemento a considerar. Revisión Sistemática

Ponce-Pincay,

Diana

2023

Kasmera

View full text Add to dashboard Cite

La COVID-19 es una enfermedad que afecta a la población mundial, representando un reto social y sanitario. El SARS-CoV-2 muestra afinidad por el sistema respiratorio, por ser la puerta de entrada y el sitio primario de replicación. Aunque las manifestaciones respiratorias sean las más frecuentes, se han reportado manifestaciones gastrointestinales, renales, neurológicas, cardiacas; entre otras. Un elemento que no ha recibido en la atención que merece es la reactivación y las coinfecciones virales. Como es bien sabido, el tratamiento de COVID-19 en sus formas graves y críticas incluyen productos biológicos, corticoesteroides, ventilación mecánica y la múltiple farmacoterapia, aunado a la fisiopatología propia de la enfermedad que es caracterizada por una tormenta de citoquinas; conlleva a que se reactiven infecciones virales que se consideran latentes y crónicas, agravando aún más el cuadro clínico. En esta revisión sistemática se ha encontrado que eventos hematológicos como la leucopenia y linfopenia junto al uso desmedido de esteroides, y la larga estancia hospitalaria puede conllevar a la reactivación de virus que pertenecen a la familia Herperviridae (Virus Epstein-Barr (VEB), Citomegalovirus (CMV) y el virus del Herpes (VHS1/2)) así como virus hepatotropos (virus de la Hepatitis B (VHB) y C(VHC), que pueden complicar el pronóstico clínico

show abstract

Suppression of hepatitis C virus replication during COVID‐19 infection

Cited by 3 publications

References 5 publications

Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate

Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate

Hyperferritinemia, chronic hepatitis C and COVID-19: what do they have in common?

Reactivación y coinfecciones virales en COVID-19: otro elemento a considerar. Revisión Sistemática

Contact Info

Product

Resources

About